Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
gptkb:cancer
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:Genentech
gptkb:Novartis |
| gptkbp:example |
gptkb:Alpelisib
gptkb:BYL719 Taselisib Serabelisib |
| gptkbp:hasApprovedDrug |
gptkb:Alpelisib
|
| gptkbp:mechanismOfAction |
inhibit phosphoinositide 3-kinase alpha
|
| gptkbp:relatedTo |
gptkb:PI3K_pathway
PIK3CA mutation |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
rash hyperglycemia |
| gptkbp:target |
gptkb:PI3K_alpha
|
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:RVMD
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
PI3Kα Inhibitors
|